InSphero at Discovery on Target 2025
Join us at Discovery on Target 2025, a premier conference focused on exploring the latest innovations in drug discovery, from NAMs to synthetic biology. This global event brings together scientists and dedicated experts in biotechnology and pharmacology, working to develop modern therapeutics that will change the future.
Don't miss out on Discovery on Target 2025 in Boston, Massachusetts from Monday, September 22 to Thursday, September 25.
Quick navigation
Meet our Team at Discovery on Target 2025


Madhu Nag, PhD
Chief Scientific Officer
Madhu Nag, PhD
Chief Scientific Officer
Madhu Lal-Nag earned her Doctor of Philosophy (PhD) in Molecular and Cellular Oncology from George Washington University and her master’s in Bioscience Business from Keck Graduate Institute.
She aims to bridge the gap between the academic and the translational aspects of cutting-edge science in oncology, metabolic diseases, and investigative toxicology. Using the results of current therapeutic regimens to creatively translate cutting-edge research to immediately serve patient needs.Director of the Trans NIH RNAi Facility at the National Center for Advancing Translational Sciences (NCATS/NIH) and Program Director at USFDA.


Scientific Talk at Discovery on Target 2025
Developing Physiologically Relevant 3D Models
Date: Monday, September 22| 17:00 -19:30
Location: Sheraton Boston


Madhu Nag, PhD
Chief Scientific Officer
Madhu Nag, PhD
Chief Scientific Officer
Madhu Lal-Nag earned her Doctor of Philosophy (PhD) in Molecular and Cellular Oncology from George Washington University and her master’s in Bioscience Business from Keck Graduate Institute.
She aims to bridge the gap between the academic and the translational aspects of cutting-edge science in oncology, metabolic diseases, and investigative toxicology. Using the results of current therapeutic regimens to creatively translate cutting-edge research to immediately serve patient needs.Director of the Trans NIH RNAi Facility at the National Center for Advancing Translational Sciences (NCATS/NIH) and Program Director at USFDA.

